[Edaily Reporter NA EUN-KYUNG ] #Rznomics Inc., a developer of RNA-based gene therapies, announced on the 10th that CEO Lee Seong-wook had purchased 1,000 shares of the company’s common stock on the open market.

With this purchase, the combined stake held by major shareholders, including related parties, now stands at 21.3%.

The company explained that this on-market purchase demonstrates a commitment to responsible management while also expressing confidence in enhancing corporate value.

Rznomics Inc.’s flagship anti-cancer gene therapy, “RZ-001” (Taspitimagen Advec), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), and clinical development is underway with a dedicated project manager (PM) assigned to the project. Last month, the company participated in Bio USA to discuss technology transfer and joint development partnerships with global pharmaceutical companies, and recently secured consecutive decisions to register U.S. patents for its Alzheimer’s disease treatment RZ-003 and next-generation anti-cancer platform RZ-002, thereby advancing its global intellectual property portfolio.

Lee Seong-wook, CEO of Rznomics Inc., stated, “As CEO, I feel a sense of responsibility toward our shareholders who are concerned about the prolonged decline in our stock price,” adding, “I decided to buy shares on the open market based on my confidence in the company’s growth potential, and I proceeded with the purchase using my personal funds within the limits of what I could immediately execute following the decision.”

He continued, “I plan to continue practicing responsible management, including considering additional purchases in the future,” and added, “I will do my utmost to restore the company’s value through research and development achievements and sound management, without being swayed by short-term market volatility.”